Will - Pharma
Will Pharma is a family-owned, independent Benelux pharmaceutical company (founded 1924) that develops, manufactures, and distributes prescription medicines, food supplements, cosmetics, and medical devices through wholesalers, pharmacies, and hospitals in Belgium, the Netherlands, and Luxembourg.
- Company typePrivate
- Founded1924
- HeadquartersWavre, Belgium
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Will - Pharma does
Will Pharma is a family-owned, independent mid-sized pharmaceutical company headquartered in Wavre, Belgium, founded in 1924 by Ludwig Frederich Will in Amsterdam. The company develops and manufactures healthcare products for the Benelux market across four categories: prescription medicines (rheumatology, gastroenterology, proctology, dermatology, gynecology), food supplements (D-Vital calcium/vitamin D line, Vitamin D Will, Vitamin C Will Boost, Cogniton cognitive line), cosmetics (Cose-Protect line), and medical devices (Willocare: Willocell, Willomesh, Willospon). Therapeutic franchises include Tempocol peppermint oil for IBS (with peer-reviewed PERSUADE study support published in Gastroenterology), the D-Vital/Vitamin D range, MYK antifungal sulconazole products, TOLPERMYO muscle relaxant, CINACALCET, and TRIANAL proctology products.
The company operates a centralized 2,500 m² Benelux distribution warehouse in Wavre, with regional offices in Schiphol-Rijk (Netherlands) and Hobscheid (Luxembourg). Its business model centers on regulated pharmaceutical product sales through wholesale distributors (Mosadex, Pluripharm, Alliance Healthcare, Brocacef, GLN, Proktovar), direct pharmacy supply, and targeted hospital supply, complemented by a business development programme for in-licensing and out-licensing partnerships. Go-to-market is sales-led via field representatives targeting pharmacists and physicians.
Revenue mechanics are based on one-time product sales of prescription medications, OTC products, food supplements, medical devices, and cosmetics, with a minimum delivery fee of EUR 12.40 per order under EUR 500. The company emphasizes full regulatory compliance with FAGG (Belgium), CBG (Netherlands), and Luxembourg authorities, sustained by an outsourced pharmacovigilance system through partner Qplus Consult.
Will - Pharma firmographics
Firmographics- Name
- Will - Pharma
- Legal name
- Will-Pharma SA
- Website
- https://willpharma.com
- Company type
- Private
- Founded year
- 1924
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Will Pharma is a family-owned, independent Benelux pharmaceutical company (founded 1924) that develops, manufactures, and distributes prescription medicines, food supplements, cosmetics, and medical devices through wholesalers, pharmacies, and hospitals in Belgium, the Netherlands, and Luxembourg.
- Ownership category
- akta.pro rank
Will - Pharma industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Generic Hospital & Institutional Products (HLAIABAL)
Keywords
Where Will - Pharma is headquartered
LocationHeadquarters
- HQ city
- Wavre
- HQ country
- Belgium
- HQ region
- Europe
Offices3 records
Markets served
Will - Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Will Pharma develops and manufactures healthcare products and sells them through wholesale distributors, pharmacies, and hospitals in the Benelux market. Products include prescription medicines, OTC products, food supplements, medical devices, and cosmetics.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Will - Pharma product offering
Product offeringCore offering
Will Pharma develops, manufactures and distributes a portfolio of prescription medicines, OTC products, food supplements, medical devices and cosmetics in the Benelux market. Therapeutic focus areas include rheumatology, gastroenterology, proctology, dermatology, gynecology and cardiovascular health. Products are sold through wholesale distributors, pharmacies and hospitals, with the company also pursuing in-licensing and out-licensing partnerships to expand its portfolio.
Product overview
Will Pharma is a family-owned independent mid-sized pharmaceutical company with a strong market position in the Benelux (Belgium, Netherlands, Luxembourg), with 100 years of experience since founding in 1924. The company develops and manufactures healthcare products in collaboration with carefully selected partners and manages all required quality and regulatory compliance for successful market launch. Will Pharma's portfolio is organized across four main product categories: (1) prescription medicines (medical products) covering therapeutic areas including rheumatology, gastroenterology, proctology, dermatology, and gynecology; (2) food supplements including the D-VITAL calcium/vitamin D line, Vitamin D Will, Vitamin C Will Boost, and the Cogniton cognitive support line; (3) cosmetics including Cose-Protect and Cose-Protect Duo for perianal skin care; and (4) medical devices including the Willocare line (Willocell, Willomesh, Willospon) for stopping capillary, venous, and minor arterial bleeding. The company's main therapeutic focus areas are rheumatology, gastroenterology, proctology, and dermatology. Will Pharma also operates a business development programme involving in-licensing (acquiring products to commercialize in the Benelux) and out-licensing (granting licenses for its products in international markets).
Differentiator
Problem solved
Functional benefit
Brands
- Willocare: Medical products sub-brand for capillary, venous, and minor arterial bleeding products including Willocell, Willomesh, and Willospon.
Products and services
- D-Vital Calcium K Medical device calcium supplement providing calcium carbonate with vitamin K2 and vitamin D3, indicated for bone health support across life stages including growth, pregnancy, menopause and elderly populations.
- Cose-Protect Duo Cosmetic intimate care cream containing polidocanol, sodium oleate, hesperidin and diosmin, formulated to soothe the perianal area and support skin regeneration.
- Vitamin D Will Registered medicine in the Vitamin D Will line offering 25,000 IU cholecalciferol per soft capsule for prevention and treatment of vitamin D deficiency, including loading-dose and osteoporosis maintenance regimens.
- Vitamin C Will Boost Food supplement releasing 1,000 mg of vitamin C using immediate and extended-release technology for immune support, antioxidant activity, wound healing and energy metabolism.
- Combizym Forte Food supplement combining protease, lipase, amylase, plant enzymes from Aspergillus oryzae, calcium and lactase for enhanced digestive enzyme support and lactose digestion.
- Tempocol Gastroenterology prescription product containing peppermint oil capsules with gastro-resistant coating for the treatment of Irritable Bowel Syndrome (IBS). Clinically proven in the PERSUADE study published in Gastroenterology to reduce abdominal pain and IBS symptoms.
- MYK-1 Crème Prescription antifungal cream containing sulconazole nitrate for the treatment of skin fungal infections.
- Willocare (Willocell, Willomesh, Willospon) Medical device hemostatic product line (sub-brand Willocare) including Willocell, Willomesh and Willospon designed to stop capillary, venous and minor arterial bleeding.
- Tolpermyo Prescription muscle relaxant medicine for the treatment of spasticity, available in 50 mg and 150 mg dosages.
- Cinacalcet Prescription medicine for internal medicine applications, available in 30 mg, 60 mg and 90 mg dosages.
- TriAnal Proctology prescription product for anal/rectal support, available in standard form and as TriAnal Zetpil suppository.
- Mediaven Forte Prescription cardiovascular product in the heart and vascular diseases category, available as 30 mg dosage.
- Donnafyta Meno Gynecology product designed for menopausal support.
- Cogniton Line Food supplement line for cognitive support including Cogniton Focus, Cogniton Focus LA, Cogniton Huperzia, and Cogniton Plus Energy LA variants.
Quantifiable outcome
- Centralizing logistics saves 12,000 transport kilometers per year
- +1 more outcomes
Companies that use Will - Pharma
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Will - Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature2 records
Will - Pharma partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered not specified and core.
- Meodynenot specifiedHealthcare partner mentioned on Will Pharma's partner page, collaborating on patient care solutions.
- PDSB (Prikkelbare Darm Syndroom Belangenvereniging)not specifiedPatient association partnership for Irritable Bowel Syndrome, collaborating on research for Tempocol effectiveness.
- Mosadexnot specifiedDutch pharmaceutical wholesale partner for distribution of Will Pharma products.
- Proktovarnot specifiedHealthcare distribution partner for Will Pharma products.
- Pluripharmnot specifiedDutch pharmacy purchasing organization and wholesale partner.
- Alliance Healthcarenot specifiedInternational pharmaceutical wholesale and distribution partner.
- Brocacefnot specifiedDutch pharmaceutical wholesale and distribution partner.
- GLN (Groothandel)not specifiedPharmaceutical wholesale partner.
- Qplus ConsultcorePharmacovigilance partner handling adverse event reporting on behalf of Will Pharma, as required by regulatory obligations.
- ZonMW (Good Use of Medicines Programme)not specifiedResearch funding partner for PERSUADE study on Tempocol peppermint oil effectiveness, funded by ZonMW GGG programme.
- MUMC+ (Maastricht UMC+)not specifiedAcademic medical center conducting PERSUADE research study on Tempocol effectiveness for IBS symptoms.
Scale indicators5 records
Recent moves10 records
Expansion highlights6 records
Will - Pharma competitors and assessment
Company assessmentBroad incumbents
- STADA Arzneimittel: European-focused generic and specialty pharma with strong Benelux pharmacy distribution; competes across OTC, generics, and specialty categories relevant to Will Pharma's portfolio.
- Ipsen: European specialty pharma with focus areas (gastroenterology, endocrinology) that overlap with Will Pharma's Tempocol and DonnaFyta Meno franchises.
- Perrigo Company: Major OTC and consumer healthcare player with deep European pharmacy presence; overlaps with Will Pharma's supplement and OTC positioning.
- Sandoz: Global generic and specialty pharma leader; competes directly with Will Pharma's generic SKUs (Cinacalcet, Tolpermyo) and exerts pricing pressure across European tender markets.
- Teva Pharmaceutical Industries: World's largest generic manufacturer with significant Benelux operations; direct overlap on generic prescription portfolio and benchmark for tender pricing pressure.
Direct peers
- Vemedia: Benelux-based specialty pharma and OTC player with comparable therapeutic categories (dermatology, gastro, women's health) and pharmacy-channel distribution model.
- Eurocept Pharmaceuticals: Dutch mid-sized specialty pharma company focused on Benelux markets with a similar in-licensing model, niche specialty product portfolio, and field sales targeting physicians and pharmacies.
- Zambon: Italian specialty pharma with established Benelux commercial footprint, competing in similar therapeutic niches including gastroenterology and women's health with branded prescription products.
- Therabel Pharmaceuticals: European specialty pharma with strong Benelux presence and a comparable mix of branded Rx, OTC, and consumer healthcare products distributed through pharmacies.
Others
- Qplus Consult: Benelux pharmacovigilance and regulatory consulting partner; classified as ecosystem/adjacent enabler rather than competitor, providing Will Pharma's PV infrastructure.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Will - Pharma social profiles
Digital presenceWill - Pharma compliance and trust
Trust signalCompliance1 record
Will - Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Will - Pharma leadership team
Management profileNumber of profiles
Profiles6 records
Will - Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Will - Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Will - Pharma
What does Will - Pharma do?
Will Pharma develops, manufactures and distributes a portfolio of prescription medicines, OTC products, food supplements, medical devices and cosmetics in the Benelux market. Therapeutic focus areas include rheumatology, gastroenterology, proctology, dermatology, gynecology and cardiovascular health. Products are sold through wholesale distributors, pharmacies and hospitals, with the company also pursuing in-licensing and out-licensing partnerships to expand its portfolio.
Is Will - Pharma a public or private company?
Will - Pharma is a private company. It is classified as family owned and is currently operating.
When was Will - Pharma founded?
Will - Pharma was founded in 1924. It employs 11 to 50 people.
Where is Will - Pharma based?
Will - Pharma is headquartered in Wavre, Belgium, in the Europe region.
How does Will - Pharma make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Will - Pharma's main competitors?
Broad incumbents on record are STADA Arzneimittel, Ipsen, Perrigo Company, Sandoz and Teva Pharmaceutical Industries. Direct peers are Vemedia, Eurocept Pharmaceuticals, Zambon and Therabel Pharmaceuticals. Qplus Consult is listed as an others.
Does Will - Pharma have an API?
No public API is recorded for Will - Pharma.
What industry is Will - Pharma in?
Will - Pharma's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2834.